GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine).”The safe use of our medicines is paramount to everyone who works for GSK and the company is committed to ensuring that all appropriate information is made available to regulators, doctors and patients.
Popularity: unranked [?]
Related posts:
- GSK Investigation Concludes
- Updated Product Information For Efexor, MHRA, UK
- Europe Wants Warnings On Champix Smoking Cessation Drug
- Research Links Coverage By Top Current Affairs Programme To Rise In Adverse Drug Reports
- Research Links Coverage By Top Current Affairs Programme To Rise In Adverse Drug Reports
Comments
No Responses to “GSK Statement On MHRA Investigation”